Evidence map›Paper›PMID 37051899›Full record

ReviewHuman vaccines & immunotherapeutics2023

Meningococcal disease within the Gulf Cooperation Council Countries.

Salah Al Awaidy, Onur Ozudogru, Selim Badur

Open access · goldAbstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Salah Al AwaidyOffice of Health Affairs, Ministry of Health, Muscat, Oman.ORCID 0000-0001-5112-3893
Onur OzudogruVaccines Medical Affairs, GSK, Dubai, UAE.ORCID 0000-0002-7668-466X
Selim BadurVaccines Scientific Affairs and Public Health, GSK, Istanbul, Turkey.ORCID 0000-0002-0490-7203
Global Vaccines (United States) · USMinistry of Health · OM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review reports on the recent epidemiology of invasive meningococcal disease (IMD) within the Gulf Cooperation Council (GCC) Countries (focusing from 2012 onwards), the existing immunization strategies and the potential for IMD resurgence. MenACWY vaccination is now established in infant or adolescent immunization programs in Saudi Arabia, Bahrain, Kuwait, and the United Arab Emirates. At present, GCC Countries do not include MenB immunization. National health surveillance reports indicate a total of 156 IMD cases reported across the GCC Countries between 2012 and 2021; between 30% and 80% of cases were reported in individuals aged ≥15 years. Lack of serogroup data hinders the assessment of vaccine impact and decision-making on additional vaccine introductions (e.g. MenB immunization). Hajj/Umrah pilgrimage and the increasing number of large-scale commercial and social events held in the GCC Countries pose a potential risk for future IMD outbreaks. Immunization policies for such events could be strengthened.

Indexed as

Meningococcal InfectionsMeningococcal VaccinesAdolescentDisease OutbreaksHumansInfantSaudi ArabiaUnited Arab EmiratesVaccinationMeningococcal VaccinesEpidemiologyGCC CountriesHajjimmunizationmass gatheringsmeningococcal diseaseoutbreaks

Identifiers

PMID37051899
PMCPMC10158544
OpenAlexW4365443038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.